Michael Freeman, Equity Research Associate, Raymond James Ltd.

A chemical engineer by training, Michael’s coverage of the cannabis sector focuses on its pure scientific, engineering, and clinical developments, yielding an evidence-driven, hyperbole-free perspective for the capital markets. True to his roots as a former iGEM competitor, heterologous cannabinoid biosynthesis—and synthetic biology, broadly—is becoming a cornerstone of this research.